Home > Treatment Options > Tumor Suppressors > Clinical Trials >
AZD2014 (Vistusertib)
Last Updated: 12/27/19
Status: Currently a NF2 Clinical Trial
| Trade Name | Vistusertib |
|---|---|
| Other Names | AZD2014, AZD-2014, AZD 2014 |
| Pharmaceutical Companies | AstraZeneca |
| NF2 Trial Availability | USA 2017 |
| Taken By | Pill (oral) |
| Tumor Target | Recurrent Meningioma |
| NF2 Trials |
|
| Inhibitor | mammalian Target of Rapamycin (mTOR); Autophagy; mTORC1/mTORC2 |
| Molecular Formula | C25H30N6O3 |
Early trial results in individuals with neurofibromatosis type 2 (NF2 / MERLIN), so far indicate the treatment may help shrink Meningioma by up to eighteen percent (18%).
Also in Trials for:
- Conditions
- Stomach Neoplasms
- Advanced Cancer
- Solid Tumor
- Prostate Cancer
- Advanced Metastatic Breast Cancer
- Glioblastoma Multiforme
- Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Module 1: Non-GCB Diffuse Large B-Cell Lymphoma
- Advanced Solid Malignancies
- Metastatic Clear Cell Renal Carcinoma
- Meningioma
- Breast Cancer|Malignant Female
- Reproductive System Neoplasm
- Neurofibromatosis 2|Meningioma
- Triple-Negative Breast Cancer|Squamous Cell Lung Cancer|Non-squamous Cell Lung Cancer With KRAS Mutations|Non-squamous Cell Lung Cancer With Wild-type KRAS
Sources
- Apra, Caroline, Matthieu Peyre, and Michel Kalamarides. "Current treatment options for meningioma." Expert review of neurotherapeutics 18.3 (2018): 241-249. DOI: https://doi.org/10.1080/14737175.2018.1429920 | Source: https://www.tandfonline.com/doi/abs/10.1080/14737175.2018.1429920
-
Pike Kurt G., Malagu Karine, Hummersone Marc G., Menear Keith A., Duggan Heather M.E., Gomez Sylvie, Martin Niall M.B., Ruston Linette, Pass Sarah L.,
"Pass Martin. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014." Bioorganic & Medicinal
Chemistry Letters, (2013)
Source: https://www.sciencedirect.com/science/article/pii/S0960894X13000413?via%3Dihub | DOI: 10.1016/j.bmcl.2013.01.019 -
Ma Xiao-Dong, Qiu Ni, Yang Bo, He Qiao-Jun, Hu Yong-Zhou. "Novel quinoline-derived mTOR inhibitors with remarkable enzymatic and cellular activities:
design, synthesis and biological evaluation." Med. Chem. Commun., (2016)
Source: http://pubs.rsc.org/en/Content/ArticleLanding/2016/MD/C5MD00401B#!divAbstract | DOI: 10.1039/C5MD00401B - "AZD2014" National Center for Biotechnology Information. PubChem Compound Database; CID=25262792, https://pubchem.ncbi.nlm.nih.gov/compound/25262792
-
Mawrin, Christian. "Looking for the needle in the haystack: Proteome-based identification of treatment targets in NF2-related nervous system tumors." EBioMedicine 16 (2017): 6-7.
Source: http://www.sciencedirect.com/science/article/pii/S2352396417300488| DOI: 10.1016/j.ebiom.2017.01.044
